| 1.48 0 (0%) | 05-31 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.13 | 1-year : | 2.38 |
| Resists | First : | 1.82 | Second : | 2.03 |
| Pivot price | 1.76  |
|||
| Supports | First : | 1.48 | Second : | 1.23 |
| MAs | MA(5) : | 1.57 |
MA(20) : | 1.81 |
| MA(100) : | 1.51  |
MA(250) : | 1.9 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 4.4 |
D(3) : | 8.8 |
| RSI | RSI(14): 27.3 | |||
| 52-week | High : | 3.88 | Low : | 0.82 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ TCRR ] has closed above bottom band by 5.7%. Bollinger Bands are 77.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.48 - 1.49 | 1.49 - 1.5 |
| Low: | 1.46 - 1.47 | 1.47 - 1.48 |
| Close: | 1.46 - 1.48 | 1.48 - 1.5 |
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Thu, 01 Jun 2023
Adaptimmune Announces Completion of Strategic Combination with TCR2 Therapeutics Creating a Preeminent Solid ... - Yahoo Finance
Tue, 07 Mar 2023
5 Penny Stocks To Buy According To Analysts, Targets Up To 952% - Penny Stocks
Tue, 07 Mar 2023
March 6 Quick Takes: Adaptimmune acquiring TCR2 Therapeutics - BioCentury
Mon, 06 Mar 2023
Adaptimmune Agrees To Merge With Another Cell Therapy Focused Company - Yahoo Finance
Mon, 06 Mar 2023
Adaptimmune Therapeutics And TCR² Therapeutics To Merge (ADAP) (TCRR) - Pulse 2.0
Mon, 06 Mar 2023
Adaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy ... - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 39 (M) |
| Shares Float | 27 (M) |
| Held by Insiders | 1.4 (%) |
| Held by Institutions | 54.3 (%) |
| Shares Short | 361 (K) |
| Shares Short P.Month | 544 (K) |
| EPS | -4.2 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.57 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -34.8 % |
| Return on Equity (ttm) | -91.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.29 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -110 (M) |
| Levered Free Cash Flow | -69 (M) |
| PE Ratio | -0.36 |
| PEG Ratio | 0 |
| Price to Book value | 0.57 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.53 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|